Glaukos touts 5-year study of glaucoma stents

This study shows that not only are Glaukos’ iStents as effective as once-daily topical travoprost in controlling IOP, but they also succeed at maintaining IOP reductions over the long-term with fewer additional medications.” Three-year outcomes of this study were published in 2016 in Ophthalmology and Therapy. The most recent article detailing five-year outcomes may be accessed online here. “This latest publication represents the first-ever five-year, protocol-driven, randomized evaluation of standalone iStent implantation in newly diagnosed glaucoma patients,” said Glaukos prez &CEO Thomas Burns. “Moreover, it adds meaningful outcomes data to the growing body of peer-reviewed evidence that implantation of a single or multiple iStents can reliably achieve sustained IOP reductions in an elegant, tissue-sparing procedure with a highly favorable safety profile.” Today’s announcement was good news for Glaukos, whose iStent recently fared worse in a two-year study that compared it to competitor Ivantis’ Hydrus Microstent. The Ivantis study touted reductions in medication use and no reoperations for patients in the Hydrus arm.      
Source: Mass Device - Category: Medical Devices Authors: Tags: Blog Clinical Trials Featured Implants News Well Optical/Ophthalmic Vision Glaukos Ivantis Source Type: news

Related Links:

Conclusions: A rapidly initiated, inflammatory (TNF-α mediated), IOP-independent pathway to glaucoma, resulting from acute anterior segment trauma or surgery, has been identified in laboratory studies. Prompt prophylactic treatment with antiinflammatory agents has been shown to be markedly neuroprotective of retinal ganglion cells, presumably capable of reducing the risk of late glaucoma.
Source: Cornea - Category: Opthalmology Tags: Special Article Source Type: research
You're reading 8 Nootropics to Stimulate Your Brain This Fall, originally posted on Pick the Brain | Motivation and Self Improvement. If you're enjoying this, please visit our site for more inspirational articles. Nootropics is a term coined by Dr. Corneliu E. Giurgea to describe a class of drugs, supplements, and other synthetic and naturally occurring compounds that improve cognitive function in our brains. They’re often called “smart drugs,” as they can help us think faster and more efficiently. Although used by pretty much everyone, these nootropic supplements are especially popular among youn...
Source: PickTheBrain | Motivation and Self Improvement - Category: Consumer Health News Authors: Tags: featured health and fitness self improvement nootropics pickthebrain Source Type: blogs
Glaukos has been open about a plan to go beyond being a “just” a medical device company. During a presentation to investors at the 37th annual J.P. Morgan Healthcare Conference, San Clemente, CA-based Glaukos’ CEO Thomas Burns said the company was transforming into a “hybrid surgical/pharmaceutical/medical device” firm. Glaukos is the frontrunner in Micro-invasive glaucoma surgery (MIGS) and was the first to have an approved device in the space. MD+DI named Glaukos’ plan to become a hybrid company as one ...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Business Source Type: news
ABSTRACT Glaucoma is the leading cause of irreversible blindness worldwide and can affect a broad array of daily activities, including driving. Recently, studies investigating the relationship between driving performance and glaucoma have received a great deal of interest. Assessment of driving behavior is not straightforward because driving is a complex skill involving significant multi-tasking ability. In this review, we summarize recent work from clinical studies investigating how glaucoma can affect driving performance. Patients with glaucoma are more likely to be involved in motor vehicle collisions when compared to h...
Source: Arquivos Brasileiros de Oftalmologia - Category: Opthalmology Source Type: research
Light-Induced Pupillary Responses in Alzheimer's Disease Pratik S. Chougule1, Raymond P. Najjar1,2, Maxwell T. Finkelstein1, Nagaendran Kandiah3,4 and Dan Milea1,2,5* 1Department of Visual Neurosciences, Singapore Eye Research Institute, Singapore, Singapore 2The Ophthalmology &Visual Sciences ACP, Duke-National University of Singapore (NUS) Medical School, Singapore, Singapore 3Department of Neurology, National Neuroscience Institute, Singapore, Singapore 4Duke-National University of Singapore (NUS), Singapore, Singapore 5Singapore National Eye Centre, Singapore, Singapore The impact of Alzheimer&...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Discussion Suppressor of cytokine signaling 1 is an essential molecule for maintaining immune homeostasis and subverting inflammation. Disorders arising from excess inflammation or SOCS1 deficiency can be potentially treated with SOCS1 mimetics (Ahmed et al., 2015). While SOCS1 has promising potential in many disorders, it should be noted that new targets and actions of SOCS1 are still being discovered and not all the effects of this protein are beneficial in autoimmune diseases and cancer. For instance, SOCS1 degrades IRS1 and IRS2, required for insulin signaling, via the SOCS Box domain, thus, limiting its potential in ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: This screening model may be adapted and scaled nationally and internationally. Referral to an ophthalmologist is warranted if abnormal or unreadable fundus images are detected or IOP is>21 mm Hg. TRIAL REGISTRATION NUMBER: NCT02390245. PMID: 30770354 [PubMed - as supplied by publisher]
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Br J Ophthalmol Source Type: research
CONCLUSION: This series represents the first report of fornix reconstruction for combined KPro/GDD surgery. Fornix reconstruction with the aid of AMT with or without OMM grafting is a relatively safe and effective way to manage complex cicatricial surface disease associated with corneal scarring and glaucoma, allowing for subsequent successful implantation of GDD and KPro in cases that were otherwise poor surgical candidates. PMID: 30742989 [PubMed - as supplied by publisher]
Source: The Ocular Surface - Category: Opthalmology Authors: Tags: Ocul Surf Source Type: research
Glaukos is probably at the top of its game when it comes down to maintaining a presence in the micro-invasive glaucoma surgery (MIGS) market. The San Clemente, CA-based company reaffirmed its laser-like focus on the market during a presentation at the 37th annual J.P. Morgan Healthcare Conference earlier on Wednesday. Glaukos’ CEO Thomas Burns began his presentation speaking on the strengths of the firm and its goals going forward. “Our mission is aspirational,” Burns said. “As a company we are seeking to transform glaucoma therapy, and in doing so we ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
CONCLUSIONS: The diode laser TSCPC is an efficient method of lowering IOP and decreasing eye pain. The "slow burn" technique has been shown its efficiency for extending the indications of cyclophotocoagulation also in glaucomatous eyes with better functional prognosis. PMID: 30534827 [PubMed - in process]
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research
More News: Blogging | Burns | Clinical Trials | Eye Implants | Eyes | Glaucoma | Medical Devices | Opthalmology | Study | Travatan